Our vision is simple: Cancer-free lives for all kids. 

Our mission is to provide direct funding for pediatric cancer research.

Our Mission

The Jeffrey Pride Foundation for Pediatric Cancer Research is an all-volunteer 501(c)3 founded in 2000 in memory of Jeffrey Pride, and in response to learning that pediatric cancer research is severely underfunded, receiving less than 4% of the National Cancer Institute’s(NCI) funding for cancer research.

The need for private funding like ours is more urgent than ever. Drug companies rarely fund pediatric cancer research in a significant way and government grants via NCI have been cut 30% over the last 10 years. At a point in time where there are so many promising ideas for research, funding is more limited than ever and life-saving research goes undone.

Important Facts to Remember About Pediatric Cancers:

*Cancer is the #1 disease killer of children in the United States, resulting in the death of more children than most other childhood diseases in combined.

*14,000 new cases of pediatric cancers are diagnosed each year (nearly 2 classrooms of children every day)

*1 in every 300 children will receive a cancer diagnosis by the age of 20

Over the past 15 years we've supported drug research, clinical trials and most recently genomic testing of children's cancer cells. This provides children with the most promising, targeted and specific treatments for their cancers. These new developments quite possibly could have changed Jeff's treatment and he and other children like him might have been healthy adults today.

Our Story

Our foundation is named after a brave little boy named Jeffrey Pride.  Jeff's short life was full of many loves. He loved his parents and sisters, his friends, his dog, school, hockey, NASCAR, video games, drawing, and building models. Jeff was a hard worker, and he fought hard in his two-year battle with leukemia.

Still, three days after his seventh birthday, Jeff died.

In the course of his battle, his parents came to realize how under funded cancer research was for children, even by the large foundations and societies that have become household names.   Surrounded by caring friends, the foundation was born with the aim of cancer-free lives for children becoming a reality.  To date,  JPF has donated over $2.1 million to the fight against Pediatric Cancer. 

What We've Achieved

  • We have helped bring about a dozen new drugs to clinical trials.  One of those drugs, Gleevec, has proven to be so successful that it is now being used as a frontline chemotherapy in high risk kids. 
  • We have helped cover the actual financial costs for kids going through clinical trials, covering their administrative expenses, those not covered by their insurance.
  • We directed funds to be used to hire and pay a statistician to facilitate faster results reporting.
  • We helped support a large scale genomic study, the only one of it’s kind being done in the world at the time, looking at cancer from the molecular level, studying the DNA of cancer cell.
  • Utilizing the valuable information gained from that study we continued genetic testing looking at markers that help determine each child’s genetic risk level, allowing very specific targeted treatments to be developed that attack only the cancer cells and leave the rest of the body unharmed.
  • In more recent funding, we continued down the same path, supporting more genetic testing that looks at how much cancer remains after the first stage of chemotherapy, the induction phase.  Once determined, very specific, targeted therapies could be developed.

WHAT WE are currently supporting

Project 1 : Improving Chimeric AntigenReceptor T-cells (CART) for Childhood ALL

  • Our first program for 2016-2017 deals with a new approach to ALL.  Researchers have found a way to use a child’s own immune system to fight cancer.  They take the immune cells from the patient’s own blood and re-engineer these cells to attack leukemia cells.  This approach has already proved effective in relapsed ALL and with our support it is being tested in a high risk group that would be destined for a bone marrow or stem cell transplant, hopefully avoiding it all together.  Because of our support for this project we are building the foundation for a nationwide trial.

Project 2 : Building The Foundation for Drugs Targeting Gene Methylation IN Children With Acute Myeloid Leukemia (AML)

  • The second project is directed towards acute myeloid leukemia or AML, the second most common form of leukemia in children.  It is difficult to treat, treatment is intense, often requires a transplant, and yet unfortunately 40% of all the kids with AML don’t make it.  And we know that re-engineering of the patient’s immune cells doesn’t work in this type of leukemia. But what researchers do know is that this type doesn’t develop because of changes in the genes but changes in the “switches” that turn genes on and off.  With our support, children across the country will have their leukemia cells studied to find which genes have “broken switches,” allowing scientists to develop drugs that can fix the “short circuits” that drive this type of leukemia.

Project 3 : The Genomics of High Risk ALL in Children With Downs Syndrome

  • The third project has to do with genetic testing of kids with Down’s Syndrome who have been diagnosed with leukemia.  What has been discovered is that kids with Down’s Syndrome have a 20-fold increased risk of developing ALLThis testing will provide information that will allow more precise, targeted therapies to be developed for this group based on their unique genetic makeup.